DLA
MRNA icon

Douglas Lane & Associates’s Moderna MRNA Stock Holding History

Douglas Lane & Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$94.1M Buy
1,343,479
+31,999
+2% +$1.66M 1.28% 18
2026
Q1 		$66.6M Buy
1,311,480
+20,015
+2% +$934K 0.96% 38
2025
Q4 		$38.1M Buy
1,291,465
+163,031
+14% +$4.43M 0.52% 81
2025
Q3 		$29.1M Buy
1,128,434
+198,269
+21% +$5.53M 0.41% 91
2025
Q2 		$25.7M Buy
930,165
+56,648
+6% +$1.49M 0.37% 92
2025
Q1 		$24.8M Buy
873,517
+99,713
+13% +$3.54M 0.36% 94
2024
Q4 		$32.2M Buy
773,804
+298,715
+63% +$14.3M 0.45% 89
2024
Q3 		$31.8M Buy
475,089
+70,889
+18% +$6.51M 0.44% 88
2024
Q2 		$48M Buy
404,200
+11,161
+3% +$1.41M 0.68% 57
2024
Q1 		$41.9M Buy
393,039
+56,901
+17% +$5.74M 0.59% 67
2023
Q4 		$33.4M Sell
336,138
-19,039
-5% -$1.6M 0.52% 76
2023
Q3 		$36.7M Buy
355,177
+94,810
+36% +$10.6M 0.62% 63
2023
Q2 		$31.6M Buy
260,367
+54,034
+26% +$7.21M 0.51% 72
2023
Q1 		$31.7M Buy
206,333
+18,408
+10% +$3.04M 0.53% 70
2022
Q4 		$33.8M Buy
187,925
+45,432
+32% +$7.43M 0.56% 61
2022
Q3 		$16.9M Buy
142,493
+29,131
+26% +$4.42M 0.31% 94
2022
Q2 		$16.2M Buy
113,362
+41,081
+57% +$5.87M 0.28% 97
2022
Q1 		$12.5M Buy
72,281
+48,917
+209% +$8.24M 0.18% 110
2021
Q4 		$5.93M Buy
23,364
+6,407
+38% +$1.87M 0.08% 115
2021
Q3 		$6.53M Buy
16,957
+6,421
+61% +$2.37M 0.09% 113
2021
Q2 		$2.48M Buy
+10,536
New +$1.88M 0.03% 129

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Douglas Lane & Associates's MRNA Position: Q2 2026 in Review

Douglas Lane & Associates increased its Moderna (MRNA) stake by 2.4% in Q2 2026, buying an estimated $1.66M and bringing the position to 1,343,479 shares worth $94.1M. The position accounts for 1.28% of the portfolio, ranked #18.

Douglas Lane & Associates first reported a position in MRNA in Q2 2021 and has held it in 21 quarters since. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Douglas Lane & Associates held 1,343,479 shares of Moderna worth $94.1M as of Q2 2026.
  • Douglas Lane & Associates bought 31,999 Moderna shares in Q2 2026, an estimated $1.66M.
  • Moderna made up 1.28% of Douglas Lane & Associates's portfolio in Q2 2026, its #18 holding.
  • Douglas Lane & Associates first reported a position in Moderna in Q2 2021 and has held it in 21 quarters since.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Douglas Lane & Associates's 13F filing for Q2 2026, filed 14 Jul 2026.